Merck’s Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients
Merck & Co Inc (NYSE: MRK) announced data from Phase 3 KEYNOTE-716 trial of Keytruda (pembrolizumab) as adjuvant treatment for patients with resected stage IIB and IIC melanoma.